KARYOPHARM THERAP.DL-0001KARYOPHARM THERAP.DL-0001KARYOPHARM THERAP.DL-0001

KARYOPHARM THERAP.DL-0001

No trades
See on Supercharts
Market capitalization
‪128.03 M‬EUR
−1.1350EUR
‪−129.65 M‬EUR
‪132.31 M‬EUR
‪107.03 M‬
Beta (1Y)
1.46

About KARYOPHARM THERAP.DL-0001

CEO
Richard A. Paulson
Headquarters
Newton
Employees (FY)
325
Founded
2008
ISIN
US48576U1060
FIGI
BBG00645T1K4
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange KARYOPHARM THERAP.DL-0001 stocks are traded under the ticker 25K.
KARYOPHARM THERAP.DL-0001 is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for KARYOPHARM THERAP.DL-0001 has a max estimate of 7.4045 EUR and a min estimate of 2.7765 EUR.
25K earnings for the last quarter are −0.28 EUR per share, whereas the estimation was −0.26 EUR resulting in a −7.14% surprise. The estimated earnings for the next quarter are −0.28 EUR per share. See more details about KARYOPHARM THERAP.DL-0001 earnings.
KARYOPHARM THERAP.DL-0001 revenue for the last quarter amounts to ‪34.06 M‬ EUR despite the estimated figure of ‪35.26 M‬ EUR. In the next quarter revenue is expected to reach ‪32.08 M‬ EUR.
Yes, you can track KARYOPHARM THERAP.DL-0001 financials in yearly and quarterly reports right on TradingView.
25K net income for the last quarter is ‪−37.90 M‬ EUR, while the quarter before that showed ‪−32.64 M‬ EUR of net income which accounts for −16.12% change. Track more KARYOPHARM THERAP.DL-0001 financial stats to get the full picture.
No, 25K doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 25K shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KARYOPHARM THERAP.DL-0001 stock right from TradingView charts — choose your broker and connect to your account.
25K reached its all-time high on Dec 8, 2014 with the price of 39.1520 EUR, and its all-time low was 0.6040 EUR and was reached on Nov 30, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 21, 2024, the company has 325.00 employees. See our rating of the largest employees — is KARYOPHARM THERAP.DL-0001 on this list?
We've gathered analysts' opinions on KARYOPHARM THERAP.DL-0001 future price: according to them, 25K price has a max estimate of 7.40 EUR and a min estimate of 2.78 EUR. Read a more detailed KARYOPHARM THERAP.DL-0001 forecast: see what analysts think of KARYOPHARM THERAP.DL-0001 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KARYOPHARM THERAP.DL-0001 EBITDA is ‪−116.88 M‬ EUR, and current EBITDA margin is −88.34%. See more stats in KARYOPHARM THERAP.DL-0001 financial statements.